Abbott has reported new data from its Volt CE Mark Study in individuals treated with PFA therapy using the Volt PFA System ...

Abbott Laboratories (NYSE:ABT) recently announced promising results from its AVEIR Conduction System Pacing study, showcasing its innovative leadless pacemaker technology. Over the last quarter, the ...

Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

CEO Robert Ford noted that Abbott has 90 manufacturing locations worldwide, with plants close to customers, redundancy, and ...

Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and ...

M.D., chief medical officer of Abbott's electrophysiology business. About the Volt CE Mark Study Abbott's Volt CE Mark Study is a prospective, single-arm, non-randomized, multicenter study ...

The Volt PFA System builds upon Abbott's leading electrophysiology (EP) portfolio by providing a single-catheter PFA approach, improving workflow by allowing for mapping, pacing, and ablating with a ...

Abbott Laboratories reports strong Q1 2025 results with 8% organic growth, double-digit EPS gains, and robust Medical Devices performance.